Oncorus Overview

  • Founded

  • 2015

Founded
  • Status

  • Public

  • Employees

  • 82

Employees
  • Stock Symbol

  • ONCR

Stock Symbol
  • Share Price

  • $0.45

  • (As of Tuesday Closing)

Oncorus General Information

Description

Oncorus Inc is a clinical-stage biopharmaceutical company focused on developing viral immunotherapies to transform outcomes for cancer patients. The company is in the process of developing intratumorally and intravenously administered product candidates designed to selectively attack and kill tumor cells and stimulate multiple arms of the immune system against tumors. Its pipeline product includes ONCR-177; ONCR-GBM; Coxsackievirus A21 and Seneca Valley Virus.

Contact Information

Website
www.oncorus.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
NAS
Primary Office
  • 50 Hampshire Street
  • Suite 401
  • Cambridge, MA 02139
  • United States
+1 (857) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Oncorus Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.45 $0.44 $0.41 - $6.08 $11.5M 26M 88.5K -$2.95

Oncorus Financials Summary

In Thousands,
USD 		TTM 30-Sep-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV (7,515) 33,871 851,044
Revenue 0 0 0 0
EBITDA (73,081) (62,879) (47,069) (30,142)
Net Income (76,334) (64,762) (48,299) (30,704)
Total Assets 164,365 201,587 182,263 50,826
Total Debt 68,542 52,072 42,608 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Oncorus Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Oncorus‘s full profile, request access.

Request a free trial

Oncorus Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion
Price		 % Owned

This information is available in the PitchBook Platform. To explore Oncorus‘s full profile, request access.

Request a free trial

Oncorus Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Oncorus Inc is a clinical-stage biopharmaceutical company focused on developing viral immunotherapies to transform outco
Drug Discovery
Cambridge, MA
82 As of 2021
00000
00000000 00000

000000

llamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in vo
0000 000000000
Boston, MA
0 As of 0000
00.000
000000000 00.000

00000

dunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco la
0000 000000000
Boston, MA
00 As of 0000
00000
0000 0000-00-00
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Oncorus Competitors (80)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Advanced Proteome Therapeutics Corporation Boston, MA 0 00.000 000000000 00.000
00000 00000000 Formerly VC-backed Boston, MA 00 00000 00000000 00000
0000000 0000000000 Formerly VC-backed Cambridge, MA 000 00000 00000000 00000
000 000000000000 Formerly VC-backed Epalinges, Switzerland 000 00.000 00000000 00.000
00000000 Formerly VC-backed Tubingen, Germany 000 00000 000000000 00000
You’re viewing 5 of 80 competitors. Get the full list »

Oncorus Patents

  • 47

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 2

    Granted

  • 7

    Pending

  • 000

    Expiring in next 12 mo

Oncorus Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220380735-A1 Dual viruses and dual oncolytic viruses and methods of treatment Pending 10-Oct-2019 00000000
AU-2020364144-A1 Dual viruses and dual oncolytic viruses and methods of treatment Pending 10-Oct-2019 00000000
CA-3157063-A1 Dual viruses and dual oncolytic viruses and methods of treatment Pending 10-Oct-2019 00000000
EP-4041902-A1 Dual viruses and dual oncolytic viruses and methods of treatment Pending 10-Oct-2019 000000000
US-20220117902-A1 Encapsulated rna polynucleotides and methods of use Pending 04-Jan-2019 C12N7/00
To view Oncorus’s complete patent history, request access »

Oncorus Executive Team (12)

Name Title Board Seat Contact Info
Theodore Ashburn Ph.D Chief Executive Officer & Board Member
Richard Wanstall Chief Financial Officer
Stephen Harbin Chief Operating Officer, Operations & Executive
John Goldberg MD Chief Medical Officer
Mitchell Finer Ph.D Founder & Executive Chairman
You’re viewing 5 of 12 executive team members. Get the full list »

Oncorus Board Members (13)

Name Representing Role Since
Alon Lazarus Ph.D Self Board Member 000 0000
Barbara Yanni JD Self Board Member 000 0000
Cameron Wheeler Ph.D Deerfield Management Board Member 000 0000
Douglas Fambrough III Self Board Member 000 0000
Luke Evnin Ph.D MPM Capital Board Member 000 0000
You’re viewing 5 of 13 board members. Get the full list »

Oncorus Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Oncorus Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Oncorus‘s full profile, request access.

Request a free trial